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Purpose or Objective: Since the beginning of clinical activity 
in 2011, approximately 600 patients has been treated with 
hadrons in CNAO (National Center for Oncological 
Hadrontherapy), among which 42 were sacral chordoma 
undergoing carbon ion radiotherapy (CIRT) with a radical 
intent. The aim of the current study is to analyze the 
feasibility of the insertion of a newly customized spacer prior 
CIRT in sacral chordoma patients, in terms of procedure 
validation and patient tolerance, in selected cases where the 
sacral chordoma is contiguous to the rectum or the bowel 
loops in order to safely escalate the dose to the tumor 
target. 
 
Material and Methods: Since 2014 , 6 consecutive sacral 
chordoma patients (3 males and 3 females) eligible for active 
scanning beam delivery CIRT at CNAO (prescribed dose 70.4 
GyE in 16 fractions), were enrolled for spacer placement at 
IRCCS Policlinico San Matteo – Dept. of General Surgery. For 
each patient silicone spacer was shaped according to 
intraoperative findings from a 10x10 cm silicone sheet with a 
width of 1 mm (Distrex, Padua, Italy). Prior to the surgery 
and clinical use, a variety of measurements was performed to 
evaluate the physical stability of the spacer during and after 
irradiation, as well as its main properties when exposed to 
carbon ion beams. During CIRT, at the end and each 3 months 
afterwards, patients were followed up for acute and late 
CIRT toxicity with clinical visit and high field magnetic 
resonance (MRI). 
 
Results: Three patients underwent laparotomic and 3- 
laparoscopic spacer placement. A representative CIRT plan 
recalculation performed on one of the enrolled patient CT 
performed before spacer insertion showed that during CIRT 
the presence of the spacer keeps digestive tract far away 
from the irradiated area, thus the radiation field is 
unaffected by rectum filling or intestine movement. Patient 
enrolled in the study did not show any gastrointestinal 
toxicity during CIRT or at follow up. Patient imaging during 
follow up did not show anatomic variations.  
 
Conclusion: Silicone spacer placement is a valuable tool for 
safe dose escalation in sacral chordoma patients undergoing 
CIRT. 
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Purpose or Objective: To determine the efficacy and the 
morbidity of the post-operative concurrent 
chemoradiotherapy in patients with advanced localized soft 
tissue sarcomas (STS) of the limbs : results of a retrospective 
analysis. 
 
Material and Methods: From 1991 to 2012, 68 patients with 
primary high grade STS of the limb were treated in our 
institution with an adjuvant concurrent chemoradiotherapy, 
following limb sparing surgery The median age was 47.5 years 
(range, 19 to 74). The most common location was the thigh 
(56%). The resection was complete (R0) and marginal (R1) in 
46 (68%), and 22 (32%), respectively. The median tumor size 
was 6 cm (range, 8 to 20cm), deep in 83% of cases, and grade 
was 2 (FNCLCC) in 28 patients (42%) and 3 in 38 (58%), 2 
missing. Adjuvant radiotherapy was delivered by 
brachytherapy (BRT) plus external radiotherapy (EBRT) in 26 
patients (38%) and by EBRT alone in 42 (62%). The median 
dose of BRT and EBRT were respectively 20Gy (range 12 to 
30Gy) and 60Gy (range, 45 to 70). The median time between 
surgery and EBRT was 48 days (range, 20 to 140). Concurrent 
chemotherapy (CT) was a combination of doxorubicin (60 
mg/m2 total dose (TD) and ifosfamide (7,5 g/m2 TD), with a 
median number of 4 cycles (range, 1-4). 
 
Results: With a median follow-up of 105 months (CI95% 89-
125), the 5-year disease-free survival and overall survival 
rates were 67%(CI95 53.9-77) and 81%(CI95 68-89); 25 
relapses were observed (6 local, 18 distant, and 1 local and 
distant). A severe (grade 3-4) hematologic toxicity was 
observed in 32% of cases, mainly leucopenia; 13 patients 
(20%) experienced a dose reduction of CT. Severe non 
hematologic complications occurred in 15 patients (22%), 
mainly acute cutaneous toxicity (14 patients, 21%). Six 
patients (10%) experienced an EBRT interruption. Severe 
wound complications were very rare (2 absesses), without 
secondary operation for wound care. In univariate analysis, 
median EBRT dose was a prognostic factor for hematologic 
severe complications, the median dose being 64Gy in patients 
with grade 3-4 toxicities vs 56Gy in patients with grade 1-2 
toxicities;p=0.01. Tumor location was a prognostic factor for 
grade 3-4 wound complications and acute dermatitis. Indeed, 
50% of complications were grade 3-4 (5/10) when tumor was 
located in upper limb, vs 17% in inferior limb (10/58); 
(p=0.035). No correlation between age, sexe, tumor size, and 
toxicity was found. 
 
Conclusion: Adjuvant concurrent chemoradiotherapy is 
efficient, feasible and well-tolerated in soft tissue sarcomas 
of the limbs. 
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Purpose or Objective: Kaposi sarcoma (KS) is a vascular 
tumor that can affect the skin and the mucosa of the 
digestive, respiratory and urinary tracts, as well as the 
lynphatic system. It is associated to human herpes virus 8 
(HHV-8). There are three principal variants: Classic KS which 
affects older people (mediterranean and jewish askenazi); 
Endemic KS which mainly affectss african children, is a 
fulminant lymphadenopathic desease, and HIV- associated KS 
which affects homosexual men. Patients with Classic KS have 
skin macules on the legs that enlarge and coalesce into 
plaques and nodules. Radiotherapy is an effective treatment 
for localized lesions. 
 
Material and Methods: We retrospectively analized patients 
with classic KS treated in our department between 2004 and 
2014. Until 2012, all our patients were treated with a 3 Gy 
per fraction, 30 Gy total dose treatment schedule. After this 
date most of our patientes were treated with a 2 Gy per 
fraction, 40 Gy total dose treatment schedule. All patients 
were treated with the same technique: two paralel-opposed 
6 Mv photom fields on both legs submerged into water, in 
order to homogenize the dose on the entire surface, and as a 
bolus effect. We observed that some patients treated with 3 
Gy per fraction schedule, had neuropathic pain in both legs, 
